arrow
K

Kathleen Chiotos

Stanford University
H指数:29
被引数:4,168

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IDSA/ACEP/ASM/PIDS/SCCM/SHEA/SHM/SIDP Multisociety Position Paper: Hospital Strategies to Improve Sepsis Outcomes

IDSA/ACEP/ASM/PIDS/SCCM/SHEA/SHM/SIDP多学会立场文件:改善脓毒症结局的医院策略

2026-08-250
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

2025年美国传染病学会关于COVID-19治疗和管理的临床实践指南更新:成人轻度至中度COVID-19的抗病毒治疗

2026-04-010
PRE
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:巴瑞替尼与托珠单抗

2026-04-010
PRE
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

2025年美国传染病学会关于COVID-19治疗和管理临床实践指南更新:Pemivibart用于暴露前预防,Vilobelimab用于危重疾病,Abatacept或Infliximab用于严重或危重疾病

2025-10-010
OAAI
Off-target Impact of Clinician Feedback Reports on Antibiotic Use in Children With Medical Complexity Hospitalized With Community-Acquired Pneumonia

社区获得性肺炎住院的复杂性医疗儿童中,临床医生反馈报告对抗生素使用的非预期影响

2025-10-010
PRE
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept

2025年美国传染病学会关于COVID-19治疗和管理的临床实践指南更新:Abatacept

2025-09-010
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:Infliximab

2025-08-011
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:Vilobelimab

2025-07-011
OAAI
Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children

儿童抗微生物耐药革兰阴性感染治疗中选定的β-内酰胺类药物建议剂量

2025-01-230
PRE
Impact of Clinician Feedback Reports on Antibiotic Use in Children Hospitalized With Community-acquired Pneumonia

临床医生反馈报告对社区获得性肺炎住院儿童抗生素使用的影响

2024-12-030
PRE
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

美国传染病学会关于新型冠状病毒肺炎管理的2024临床实践指南更新: Anti-SARS-CoV-2中和抗体Pemivibart用于暴露前预防

2024-10-291
PRE
International Consensus Criteria for Pediatric Sepsis and Septic Shock

小儿脓毒症和脓毒性休克的国际共识标准

2024-02-2784
OA
Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper

在按绩效付费和电子质量措施的时代改善败血症的结果: IDSA/ACEP/PIDS/SHEA/SHM/SIDP联合立场文件

2023-10-1314
OA
Maternal Vaccination and Risk of Hospitalization for Covid-19 Among Infants
2023-01-010
PRE